Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
US FDA Performance Tracker Approvals Drug Review

Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal

  • News

Executive Summary

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

You may also be interested in...



BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation

Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.

April US FDA Approval Decisions To Cover Cardiomyopathy, CNS And China-Developed Cancer Drugs

Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.

Keeping Track: Orphan Drugs Aplenty At US FDA, From Pyrukynd Approval To Adagrasib Standard Review

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Table

View full table

Related Content

Pink Sheet

Topics

Related Companies

Tags:
US FDA Performance Tracker Approvals Drug Review
Latest Headlines

EU CHMP Opinions And MAA Updates

As New Tech Emerges For Early Research, FDA Chief Scientist Says Diversity Must Start In Preclinical Development

Pilot Phase Of Operation Warp Speed For Rare Diseases Beginning Soon

Platform Technology Designation A Gene Therapy Opportunity, OTP Director Verdun Says

See All
UsernamePublicRestriction

Register

PS146002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By